Vertex Pharma (VRTX) Tops Q1 EPS by 2c; Reaffirms
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $546.12 -2.12%
Revenue Growth %: +10.7%
Financial Fact:
Net loss: -39.54M
Today's EPS Names:
PMCB, CULP, HURC, More
Revenue Growth %: +10.7%
Financial Fact:
Net loss: -39.54M
Today's EPS Names:
PMCB, CULP, HURC, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $3.05, $0.02 better than the analyst estimate of $3.03. Revenue for the quarter came in at $2.37 billion versus the consensus estimate of $2.34 billion.
GUIDANCE:
Vertex Pharma reaffirms FY2023 revenue of $9.55-9.7 billion, versus the consensus of $9.7 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- John Wiley & Sons, Inc. (WLYB) Misses Q1 EPS by 2c ; Offers Guidance
- Planet Labs (PL) Tops Q2 EPS by 4c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
